| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TRAIL-R2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6346H9832N1720O2002S42 |
| Molar mass | 143601.02 g·mol−1 |
  (what is this?) (verify) | |
Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.[1][2]
HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology.[3]
Development was discontinued in 2015.[4]
- ^ "Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab" (PDF). American Medical Association. Archived from the original (PDF) on 2012-02-20.
- ^ Marini P (December 2006). "Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2". Current Opinion in Molecular Therapeutics. 8 (6): 539–46. PMID 17243490.
- ^ "TRAIL Receptor Antibodies". Human Genome Sciences, Inc. Archived from the original on 2008-05-16. Retrieved 2010-05-12.
- ^ "Lexatumumab". AdisInsight. Springer Nature Switzerland AG.